LON:AMYT Amryt Pharma (AMYT) Share Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free AMYT Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range 143▼ 14352-Week Range N/AVolume90,727 shsAverage Volume469,552 shsMarket Capitalization£457.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Amryt Pharma alerts: Email Address Ad Wealthpin ProOne trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training. About Amryt Pharma Stock (LON:AMYT)Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.Read More Ad Wealthpin ProOne trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training. AMYT Stock News HeadlinesApril 17, 2024 | americanbankingnews.comAmryt Pharma (LON:AMYT) Share Price Crosses Below 50-Day Moving Average of $143.00March 22, 2023 | finance.yahoo.comAmryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi FarmaceuticiApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.January 16, 2023 | msn.comChiesi Farmaceutici S.p.A. to acquire Amryt PharmaJanuary 10, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Amryt Pharma Plc BuyoutJanuary 9, 2023 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMYT, CINC, ALBOJanuary 9, 2023 | technews.tmcnet.comAMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to ShareholdersJanuary 8, 2023 | news.yahoo.comItaly's Chiesi Farmaceutici to buy Amryt Pharma in a $1.48 billion dealApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.January 8, 2023 | au.finance.yahoo.comChiesi Farmaceutici S.p.A. to Acquire Amryt Pharma PlcDecember 5, 2022 | ca.finance.yahoo.comEuropean Commission approves Mycapssa® for the treatment of AcromegalyOctober 31, 2022 | nz.finance.yahoo.comAmryt Supports Acromegaly Awareness Day 2022October 17, 2022 | finance.yahoo.comAmryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin)October 15, 2022 | seekingalpha.comAMYT Amryt Pharma plcAugust 6, 2022 | seekingalpha.comAmryt Pharma plc (AMYT) CEO Joseph Wiley on Q2 2022 Results - Earnings Call TranscriptAugust 4, 2022 | finance.yahoo.comAmryt Pharma PLC Sponsored ADR (AMYT) Reports Q2 Loss, Tops Revenue EstimatesJuly 30, 2022 | morningstar.comAmryt Pharma PLC ADR Stock Quote AMYTJune 27, 2022 | seekingalpha.comAmryt Pharma appoints Dr Tracy Cunningham as Chief Medical OfficerJune 25, 2022 | marketwatch.comAmryt to Pursue Formal FDA Resolution for Oleogel-S10 >AMYTJune 24, 2022 | finance.yahoo.comFilsuvez's European Approval Adds Growth Driver For Amryt PharmaJune 24, 2022 | nasdaq.comAmryt Pharma To Submit Formal Dispute Resolution Request For Oleogel-S10 NDAMay 17, 2022 | finance.yahoo.comAmryt Announces Details of EMA Contingent Value Rights PaymentMay 11, 2022 | uk.finance.yahoo.comAmryt Announces New Patent for Mycapssa®May 8, 2022 | seekingalpha.comAmryt Pharma PLC (AMYT) CEO Joseph Wiley on Q1 2022 Results - Earnings Call TranscriptApril 22, 2022 | seekingalpha.comAmryt stock rises 10% as EMA panel backs approval of Filsuvez to treat skin disorder in EUApril 13, 2022 | finance.yahoo.comAmryt Posts Long-Term Safety, Efficacy Mycapssa Data In Acromegaly PatientsMarch 17, 2022 | nasdaq.comAmryt Pharma PLC Rings the Opening BellSee More Headlines Receive AMYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:AMYT Previous SymbolLON:FAST CUSIPN/A CIKN/A Webwww.amrytpharma.com Phone+44-20-34155730FaxN/AEmployees2,020Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio66.05 Current Ratio1.80 Quick Ratio1.14 Sales & Book Value Annual Sales£210.24 million Price / Sales2.17 Cash FlowGBX 38.90 per share Price / Cash Flow3.68 Book ValueGBX 96.60 per share Price / Book1.48Miscellaneous Outstanding Shares319,657,000Free FloatN/AMarket Cap£457.11 million OptionableNot Optionable BetaN/A Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Joseph A. Wiley (Age 50)CEO & Director Comp: $1.72MMr. Rory P. Nealon (Age 53)CFO, COO & Company Sec. Comp: $931kMs. Elizabeth Varki Jobes J.D. (Age 54)Sr. VP & Global Chief Compliance Officer Mr. John McEvoyGen. CounselMr. Stephen JoyceVP of Global MarketingMs. Julie EastwoodHead of HRMs. Derval O'CarrollHead of Regulatory AffairsMr. Gerry GilliganHead of Manufacturing Supply ChainDr. Mark Sumeray (Age 55)Chief Medical Officer Mr. David AllmondChief Commercial OfficerMore ExecutivesKey CompetitorsBenchmarkLON:BMKAlliance PharmaLON:APHBeximco PharmaceuticalsLON:BXPAllergy TherapeuticsLON:AGYAnimalcare GroupLON:ANCRView All Competitors AMYT Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Amryt Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amryt Pharma investors own include The Parkmead Group (PMG), Himax Technologies (HIMX), Atalaya Mining (ATYM), Concepta PLC (CPT.L) (CPT), Faroe Petroleum (FPM), Vectura Group (VEC), Xcite Energy (XEL), Bowleven (BLVN), BTG (BTG) and Cavium (CAVM). How do I buy shares of Amryt Pharma? Shares of AMYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:AMYT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersGreat Crypto BullWeiss RatingsThe Next Nvidia?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amryt Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
